RECITALSSettlement Agreement • March 12th, 2010 • Cytodyn Inc • Pharmaceutical preparations • California
EXHIBIT 10.5 MASTER AGREEMENT FOR PROFESSIONAL SERVICES THIS MASTER AGREEMENT ("the Agreement"), which sets forth the terms and conditions of services to be provided by Symbion Research International, Inc., a California corporation with its principal...Master Agreement • October 21st, 2004 • Cytodyn Inc • Non-operating establishments
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 9th, 2018 • CytoDyn Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [ ], 2018 between CYTODYN INC., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
COMMON STOCK PURCHASE WARRANT CYTODYN INC.CytoDyn Inc. • July 20th, 2017 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 15, 2016 (the “Initial Exercise Date”) and on or prior to the close of business on September 13, 2021 (the “Termination Date”) but not thereafter, to subscribe for and purchase from CytoDyn Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued by the Company as of the date hereof pursuant to Section A.2 of the Engagement Agreement, dated as of March 29, 2016, between the Company and Rodman and Renshaw, a unit of H.C. Wainwright & Co., LLC.
CHANGE OF CONTROL AGREEMENT This Change of Control Agreement (the "Agreement") is entered into this 31st day of May , 2004 (the "Effective Date") by and between CytoDyn, Inc., a Colorado corporation (the "Company") with its principal place of business...Change of Control Agreement • September 14th, 2004 • Cytodyn Inc • Non-operating establishments • New Mexico
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 12th, 2016 • CytoDyn Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 12, 2016, between CytoDyn Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 10.2 AMENDMENT NUMBER 1 TO ACQUISITION AGREEMENT Rexray Corporation and CytoDyn of New Mexico. Inc. entered into an Acquisition Agreement dated September 30, 2003. The parties wish to amend that Agreement as set forth in this Amendment Number...Acquisition Agreement • January 13th, 2005 • Cytodyn Inc • Non-operating establishments
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 12th, 2016 • CytoDyn Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2016, between CytoDyn Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT CYTODYN INC.CytoDyn Inc. • December 27th, 2019 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ] (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from CytoDyn Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ACQUISITION OF ADVANCED GENETIC TECHNOLOGIES, INC. by CYTODYN, INC. AGREEMENT AND PLAN OF ACQUISITIONCytodyn Inc • February 5th, 2007 • Pharmaceutical preparations • Delaware
THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "1933 ACT"), NOR REGISTERED UNDER ANY STATE SECURITIES LAW, AND ARE "RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144 UNDER...Agreement • March 10th, 2004 • Cytodyn Inc • Non-operating establishments
FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • January 14th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Colorado
THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made and entered into as of the [ ] day of [ ], 20[ ], by and between CytoDyn Inc., a Colorado corporation (the “Company”), and [insert name] (“Indemnitee”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 29th, 2021 • CytoDyn Inc. • Pharmaceutical preparations • Utah
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 23, 2021, is entered into by and between CYTODYN INC., a Delaware corporation (“Company”), and UPTOWN CAPITAL, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
ARTICLE 2 REPRESENTATIONS AND WARRANTIESCytodyn Inc • July 21st, 2006 • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • January 9th, 2020 • CytoDyn Inc. • Pharmaceutical preparations • Washington
This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of November 13, 2019 (the “Effective Date”), is by and between CYTODYN INC., a Delaware corporation (the “Company”) and Craig Eastwood (the “Employee”).
SECURITY AGREEMENTSecurity Agreement • April 29th, 2021 • CytoDyn Inc. • Pharmaceutical preparations • Utah
THIS SECURITY AGREEMENT (this “Agreement”), dated as of April 23, 2021, is executed by CytoDyn Inc., a Delaware corporation (“Debtor”), in favor of Uptown Capital, LLC, a Utah limited liability company (“Secured Party”).
Amendment Number 1 To Patent License AgreementNumber • March 21st, 2005 • Cytodyn Inc • Non-operating establishments
Exhibit 10.5.2 BUY-SELL AGREEMENT BETWEEN CYTODYN, INC. ---------------------------------------- AND SYMBION RESEARCH INTERNATIONAL, INC. ---------------------------------------- 1.1 This Agreement is effective as of January 5, 2005 and is entered...Buy-Sell Agreement • January 12th, 2005 • Cytodyn Inc • Non-operating establishments • California
AGREEMENT ---------Personal Services Agreement • September 14th, 2004 • Cytodyn Inc • Non-operating establishments • New Mexico
THE GENERAL HOSPITAL CORPORATION CLINICAL TRIAL AGREEMENT (Investigator- Initiated) This Clinical Trial Agreement ("Agreement") is made as of the 28 day of September, 2009 ("Effective Date") between CytoDyn, Inc., a publicly traded corporation...Clinical Trial Agreement • September 29th, 2009 • Cytodyn Inc • Pharmaceutical preparations • Massachusetts
Exhibit 99.1 CYTODYN, INC. PROMISSORY NOTE CYTODYN, INC., a Colorado corporation (the "Company"), for value received, hereby promises to pay to the order of ____________ (the "Holder") or the Holder's registered assigns, the sum of ___________________...Cytodyn Inc • March 11th, 2005 • Non-operating establishments • Colorado
SUBSCRIPTION AGREEMENTSubscription Agreement • November 7th, 2019 • CytoDyn Inc. • Pharmaceutical preparations • New York
R E C I T A L S ---------------Non-Exclusive License Agreement • July 21st, 2006 • Cytodyn Inc • Pharmaceutical preparations • Massachusetts
SUBSCRIPTION AGREEMENTSubscription Agreement • October 22nd, 2019 • CytoDyn Inc. • Pharmaceutical preparations • New York
The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
EMPLOYMENT AGREEMENTEmployment Agreement • December 26th, 2018 • CytoDyn Inc. • Pharmaceutical preparations • Washington
This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of December 22 2018 (the “Effective Date”), is by and between CYTODYN INC., a Delaware corporation (the “Company”) and Nitya G. Ray (the “Employee”).
PLACEMENT AGENT AGREEMENT August 12th, 2019Placement Agent Agreement • August 29th, 2019 • CytoDyn Inc. • Pharmaceutical preparations
This Placement Agent Agreement (“Agreement”) is made by and between CytoDyn Inc., a Delaware corporation (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date first above written. The Company hereby engages the Placement Agent to assist the Company as its non-exclusive placement agent in arranging an offering of its equity securities (the “Securities”) which will be subject to a registration statement (the “Registration Statement”) on Form S-3 previously declared effective by the United States Securities and Exchange Commission (the “SEC”) , on terms to be determined by the parites hereto (the “Offering”). The terms of the Offering will be more fully described in the definitive transaction documents pertaining to the Offering, to be prepared by the Company, with the assistance of the Placement Agent.
J.P. TURNER & COMPANY, L.L.C. INVESTMENT BANKING DIVISION December 28, 2005 Mr. Allen D. Allen President CytoDyn, Inc. 227 E. Palace Ave, Suite M Santa Fe, NM 87501 Re: Financial Representative Agreement with J.P. Turner & Company, LLC Dear Mr. Allen,...Cytodyn Inc • January 4th, 2006 • Pharmaceutical preparations
J.P. TURNER & COMPANY, LLC INVESTMENT BANKING November 25, 2003 (the "Effective Date") -------------- Mr. Allen D. Allen Chief Executive Officer CytoDyn, Inc. 4236 Longridge Avenue, Suite 302 Studio City, CA 91604 Re: Financial Representative...Cytodyn Inc • September 14th, 2004 • Non-operating establishments
CYTODYN, INC. PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT FOR EMPLOYEES I recognize that CytoDyn, Inc. a Colorado corporation, (hereinafter collectively called the "Company"), is engaged in a continuous program of research and development of...And Inventions Agreement • September 14th, 2004 • Cytodyn Inc • Non-operating establishments
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2020 • CytoDyn Inc. • Pharmaceutical preparations • Washington
This Employment Agreement (this “Agreement”), dated as of March 16, 2020 (the ”Effective Date”), is by and between CytoDyn Inc., a Delaware corporation (the “Company”) and Arian Colachis (the “Executive”).
SUBSCRIPTION AGREEMENTSubscription Agreement • October 12th, 2016 • CytoDyn Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • October 23rd, 2023 • CytoDyn Inc. • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”) is effective August 15, 2023 (the “Effective Date”), by and between CYTODYN INC., a Delaware corporation (the “Company”) and TYLER BLOK (the “Executive”).
R E C I T A L S ---------------Sponsored Research Agreement • July 21st, 2006 • Cytodyn Inc • Pharmaceutical preparations • Massachusetts
Certain identified information has been excluded because it is both not material and would likely cause competitive harm if publicly disclosed. MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and CYTODYN INC.Master Services Agreement • August 14th, 2019 • CytoDyn Inc. • Pharmaceutical preparations • New York
This Master Services Agreement (this “MSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between CytoDyn Inc., a Delaware corporation having its principal place of business at 1111 Main Street, Suite 660, Vancouver, WA 98660 (“Client”), and Samsung BioLogics Co., Ltd., a company with offices at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SUBSCRIPTION AGREEMENTSubscription Agreement • August 29th, 2019 • CytoDyn Inc. • Pharmaceutical preparations • New York
cause to be delivered to the Investor one Common Stock Purchase Warrant, in substantially the form attached hereto as Appendix II, evidencing Warrants to purchase the number of Warrant Shares set forth on the Signature Page and (c) the aggregate purchase price for the Shares and Warrants being purchased by the Investor will be delivered by or on behalf of the Investor to the Company.
